The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Influenza viruses have continued to steadily circulate within Atlanta and Georgia communities as the state contends with ...

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

The Federal Public Service Commission (FPSC) has officially confirmed that the Central Superior Services (CSS) 2025 examination will proceed as planned, beginning tomorrow (Saturday, 5, 2025).

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

According to police sources, coordination between the district administration, security agencies, and other departments had ...

The Islamabad High Court (IHC) has rejected a petition that sought to delay the upcoming Central Superior Services (CSS) 2025 ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...